小儿哮喘治疗中采用白三烯受体拮抗剂顺尔宁的临床效果

Clinical effect of leukotriene receptor antagonist montelukast in the treatment of asthma in children

目的分析小儿哮喘治疗中采用白三烯受体拮抗剂顺尔宁的临床效果。方法选择我院2013年1月~2016年3月收治的110例哮喘患儿作为本次的研究对象,分为常规组与实验组,每组患儿各55例。其中对常规组患儿采取一般治疗方案,实验组患儿在此基础上加用白三烯受体拮抗剂顺尔宁治疗,对两组临床疗效进行分析对比。结果实验组治疗总有效率为96.36%,常规组为81.82%,差异有统计学意义(P<0.05);实验组临床症状消失时间相比常规组明显较短,差异有统计学意义(P<0.05);实验组与常规组的不良反应发生率分别为1.82%与3.64%,差异无统计学意义(P>0.05);实验组与常规组的疾病复发率分别为5.45%与20.00%,差异有统计学意义(P<0.05)。结论对哮喘患儿采取白三烯受体拮抗剂顺尔宁进行治疗可促进患者临床症状的改善,药物具有较高的安全性,可明显提升患者生存质量。

Objective To analyze the clinical effect of leukotriene receptor antagonist montelukast in the treatment of asthma in children. Methods I lO children with asthma cured in our hospital from＇January 2013 to March 2016 were selected as the study object.They were divided into routine group and experimental group with 55 cases in each. Patients in routine group were treated with general treatment scheme,and patients in experimental group were treated with leukotriene receptor antagonist montelukast treatment on the basis of general treatment.The clinical efficacy of the two groups were analyzed and compared. Results The total effective rate was 96.36% in the experimental group,81.82% in the routine group,and （P 〈 0.05）.The clinical symptom disappearance time of the experimental group was shorter than that of the conventional group,（P 〈 0.05）.The incidence of adverse reactions in the experimental group and the routine group were 1.82% and 3.64%,respectively, and（P〈0.05）.The recurrence rates of the experimental group and the routine group were 5.45% and 20%, respectively,and（P 〈 0.05）. Conclusion The leukotriene receptor antagonist singulair treatment can improve the patient＇ s clinical symptoms of asthma in children. The drug has high safety,and it can obviously improve the quality of life of the patients.